Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma

Eisai Co., Ltd.300 enrolled

Overview

This surveillance's objectives are: 1. Unknown adverse reactions 2. Incidences of adverse drug reaction 3. Factors considered to have effect to safety and effectiveness

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Hepatocellular Carcinoma

Interventions

E7040DEVICE

E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion criteria: Patients with Hepatocellular carcinoma Exclusion criteria: None

Locations (1)

Unnamed facility

Multiple Locations, Japan

Outcomes

Primary Outcomes

Safety and Tolerability as measured by Adverse Events

Time frame: Up to 30 days

Secondary Outcomes

Efficacy of DC bead as assessed by embolic performance

Time frame: Up to 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.